136 related articles for article (PubMed ID: 17142738)
21. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
22. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
Dolan BP; Gibbs KD; Ostrand-Rosenberg S
J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
[TBL] [Abstract][Full Text] [Related]
23. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
24. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
[TBL] [Abstract][Full Text] [Related]
25. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen.
Gold JS; Ferrone CR; Guevara-Patiño JA; Hawkins WG; Dyall R; Engelhorn ME; Wolchok JD; Lewis JJ; Houghton AN
J Immunol; 2003 May; 170(10):5188-94. PubMed ID: 12734366
[TBL] [Abstract][Full Text] [Related]
26. 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines.
Sharma RK; Schabowsky RH; Srivastava AK; Elpek KG; Madireddi S; Zhao H; Zhong Z; Miller RW; Macleod KJ; Yolcu ES; Shirwan H
Cancer Res; 2010 May; 70(10):3945-54. PubMed ID: 20406989
[TBL] [Abstract][Full Text] [Related]
27. Efficient generation of survivin-specific cytotoxic T lymphocytes from healthy persons in vitro: quantitative and qualitative effects of CD4+ T cells.
Kim EK; Cho HI; Yoon SH; Park MJ; Sohn HJ; Kim HJ; Oh ST; Kim TG
Vaccine; 2008 Jul; 26(32):3987-97. PubMed ID: 18584926
[TBL] [Abstract][Full Text] [Related]
28. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
[TBL] [Abstract][Full Text] [Related]
29. [The study of anti-tumor activities of DC vaccine loaded with multi-epotipes of survivin].
Guo M; Wang XY; Song WZ; Li XN; Liang X; Li Y; Huang ZL
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Nov; 27(11):1180-3. PubMed ID: 22078442
[TBL] [Abstract][Full Text] [Related]
30. Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?
Strioga MM; Darinskas A; Pasukoniene V; Mlynska A; Ostapenko V; Schijns V
Vaccine; 2014 Jul; 32(32):4015-24. PubMed ID: 24837511
[TBL] [Abstract][Full Text] [Related]
31. Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor.
Lu Y; Wei YQ; Tian L; Zhao X; Yang L; Hu B; Kan B; Wen YJ; Liu F; Deng HX; Li J; Mao YQ; Lei S; Huang MJ; Peng F; Jiang Y; Zhou H; Zhou LQ; Luo F
J Immunol; 2003 Mar; 170(6):3162-70. PubMed ID: 12626574
[TBL] [Abstract][Full Text] [Related]
32. Survivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignancies.
Friedrichs B; Siegel S; Andersen MH; Schmitz N; Zeis M
Leuk Lymphoma; 2006 Jun; 47(6):978-85. PubMed ID: 16840186
[TBL] [Abstract][Full Text] [Related]
33. Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells.
Schnell S; Young JW; Houghton AN; Sadelain M
J Immunol; 2000 Feb; 164(3):1243-50. PubMed ID: 10640737
[TBL] [Abstract][Full Text] [Related]
34. Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.
Johannsen A; Genolet R; Legler DF; Luther SA; Luescher IF
J Immunol; 2010 Sep; 185(6):3445-55. PubMed ID: 20733200
[TBL] [Abstract][Full Text] [Related]
35. Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein.
Cho HI; Kim EK; Park SY; Lee SK; Hong YK; Kim TG
Cancer Lett; 2007 Dec; 258(2):189-98. PubMed ID: 17931768
[TBL] [Abstract][Full Text] [Related]
36. Tumors hamper the immunogenic competence of CD4+ T cell-directed dendritic cell vaccination.
Zimmermann VS; Casati A; Schiering C; Caserta S; Hess Michelini R; Basso V; Mondino A
J Immunol; 2007 Sep; 179(5):2899-909. PubMed ID: 17709504
[TBL] [Abstract][Full Text] [Related]
37. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
[TBL] [Abstract][Full Text] [Related]
38. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.
Rosalia RA; Cruz LJ; van Duikeren S; Tromp AT; Silva AL; Jiskoot W; de Gruijl T; Löwik C; Oostendorp J; van der Burg SH; Ossendorp F
Biomaterials; 2015 Feb; 40():88-97. PubMed ID: 25465442
[TBL] [Abstract][Full Text] [Related]
39. Dendritic cells generated in the presence of interferon-alpha stimulate allogeneic CD4+ T-cell proliferation: modulation by autocrine IL-10, enhanced T-cell apoptosis and T regulatory type 1 cells.
Carbonneil C; Saidi H; Donkova-Petrini V; Weiss L
Int Immunol; 2004 Jul; 16(7):1037-52. PubMed ID: 15184347
[TBL] [Abstract][Full Text] [Related]
40. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]